Annals of Indian Academy of Neurology
  Users Online: 3595 Home | About the Journal | InstructionsCurrent Issue | Back IssuesLogin      Print this page Email this page  Small font size Default font size Increase font size

Table of Contents
AIAN REVIEW
Year : 2023  |  Volume : 26  |  Issue : 1  |  Page : 17-32
 

Anti-N-methyl D-aspartate receptor encephalitis in India: A literature review


1 Department of Neurology, G. B. Pant Institute of Postgraduate Medical Education and Research, New Delhi, India
2 Department of Internal Medicine, Vivekananda Polyclinic and Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

Date of Submission12-Jun-2022
Date of Decision22-Aug-2022
Date of Acceptance25-Aug-2022
Date of Web Publication25-Jan-2023

Correspondence Address:
Debashish Chowdhury
Department of Neurology, G. B. Pant Institute of Postgraduate Medical Education and Research, New Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/aian.aian_519_22

Rights and Permissions

 

   Abstract 


Anti N-methyl D-aspartate receptor encephalitis (NMDAR-E) though rare, is currently considered as the commonest antibody mediated encephalitis in the world. No review on perspectives of NMDAR-E from India is available. The aim of the study was to review all the cases of NMDAR-E reported from India until June 2021 in terms of clinical features, diagnosis, and treatment, and perform a comparison of adult and paediatric cases. A literature review of NMDAR-E case reports/case series published from India till June 2021 was done. Demography, clinical profile, triggers, electroencephalography (EEG), neuroimaging, treatment details and outcomes were analysed. Sixteen case series and 35 case reports with a total of 249 cases were analysed. 82% of cases were from paediatric age group. The female to male ratio was 3:1. Psychiatric deficits, movement disorders, seizures, and language abnormalities were the most common clinical features. MRI brain abnormalities were seen in 45% patients. Electroencephalographic abnormalities were seen in 85% of patients. Infective triggers (herpes simplex virus and various other agents) were reported in 11% of the cases. Pediatric patients as compared with adults had more encephalopathy, autonomic dysfunctions, and normal imaging whereas the latter had more cognitive dysfunctions and delta brush pattern in electroencephalography (p<0.005). Therefore, to conclude, this literature review suggests that overall, the clinical spectrum of Indian cases is like cases described from other parts of the world. However, most reported cases from India belonged to paediatric age group who had more encephalopathy, autonomic dysfunctions, and normal brain imaging compared to adults. A few novel infectious agents as triggers were described from India.


Keywords: Adult, anti-N-methyl D-aspartate receptor encephalitis, delta brush pattern, pediatric, triggers


How to cite this article:
Chowdhury D, Panda AK, Gupta A, Chowdhury S, Duggal A, Koul A. Anti-N-methyl D-aspartate receptor encephalitis in India: A literature review. Ann Indian Acad Neurol 2023;26:17-32

How to cite this URL:
Chowdhury D, Panda AK, Gupta A, Chowdhury S, Duggal A, Koul A. Anti-N-methyl D-aspartate receptor encephalitis in India: A literature review. Ann Indian Acad Neurol [serial online] 2023 [cited 2023 Feb 1];26:17-32. Available from: https://www.annalsofian.org/text.asp?2023/26/1/17/361561





   Introduction Top


After its first description in 2007,[1] “Anti N-methyl D-aspartate receptor encephalitis” (NMDAR-E) has become the most common cause of antibody-mediated encephalitis in the world and is characterized by the presence of cerebrospinal fluid (CSF) antibodies against the Glutamate N1 subunit of the NMDAR.[2],[3] However, the overall incidence of the disease is rare, and it has been estimated that about 1.5 per million per year suffer from this disease.[4] Over the last decade, many cases and series have been published in different regions of the world updating the clinical spectrum with regard to the demography, symptoms, imaging, and triggers of NMDAR-E. The striking presence of psychiatric and behavioral symptoms at onset and multiple combinations of neurological manifestations such as movement disorders (MD), seizures, speech disorders, altered consciousness, insomnia, and autonomic dysfunctions characterizes the disease and hence may be challenging to diagnose clinically. However, early diagnosis of NMDAR-E is important as the disease is treatable with immunomodulation. Another important feature of NMDAR-E is its association with various tumors (especially ovarian teratoma) and infectious agents such as Herpes Simplex encephalitis.[2],[3],[4] Lately, non-HSV and other CNS/systemic infections are increasingly being implicated as triggers for NMDAR-E.[5],[6] It would be interesting to analyze Indian cases from this perspective as infectious diseases are common in India. Further, a comprehensive review of the available literature on NMDAR-E from India shall be useful by highlighting the differences in clinical and management details of this disease, if any. Also, over the years, relatively large case series and reviews have highlighted some differences between adult and pediatric NMDAR-E at the onset.[4],[7] Therefore, we aimed to present an analysis of the literature review of all the NMDAR-E cases reported from India till June 2021 focusing on the clinical spectrum, investigations, triggers, and outcomes. We also compared the differences between the clinical profile and the outcome of pediatric and adult NMDAR-E cases.


   Methods Top


We did a literature search on PUBMED for case reports (less than three cases) and case series (three or more cases) published from India up till June 2021 using the following MeSH: (anti-N-methyl-d-aspartate receptor encephalitis) OR (N-methyl-d-aspartate antibody encephalitis) OR (anti-NMDAR encephalitis) OR (anti-NMDA receptor encephalitis) OR (NMDA receptor encephalitis) OR (anti-N-methyl-d-aspartate receptor antibody encephalitis) and India in the English language. The demographic details, clinical symptoms, imaging, electroencephalography (EEG), and treatment details available in the reports were recorded and analyzed [Figure 1].
Figure 1: The PRISMA diagram detail the search and selection process applied during our systematic literature search

Click here to view


Patients of all age groups were included, and age was represented as “years.” Patients who were 18 years or above were classified as adults and those below 18 years of age were classified as pediatric patients. Various clinical symptoms were recorded and grouped as MD (tremor, dystonia, chorea, oro-mandibular movements, dyskinesia), seizures (focal, generalized tonic–clonic seizures, nonconvulsive status epilepticus, refractory seizures, infantile spasms, and status epilepticus), cognitive deficits (memory disturbances, attention disturbances, anterograde amnesia, calculation impairment, visuospatial impairment), psychiatric abnormalities (personality changes, psychomotor disturbance, irritability, anxiety, hallucinations, psychosis delusions, catatonia, agitation, and aggression), encephalopathy (confusion, altered sensorium, deterioration of consciousness, altered mental state), sleep disturbances (insomnia, excessive sleeping, disturbed sleep, decreased sleep), autonomic dysfunction (dysautonomia, sweating, tachycardia, blood pressure fluctuation), and language abnormalities (aphasia, dysphasia, mutism). MRI brain was categorized as normal or abnormal. When details were available, specific parts of the brain that were involved were noted such as the midbrain (MB), basal ganglia (BG), thalamus (TH), temporal lobe (T), frontal (F), occipital lobe (O), parietal (P), insula (ins), meninges (MEN), and white matter (WM). Treatment details were grouped as first-line and second-line treatment. Steroids [methylprednisolone (MPS)], intravenous human immunoglobulin (IVIG), and plasma exchange (PLEX) were grouped as first-line treatment, whereas rituximab (RTX), cyclophosphamide, and other agents were grouped as second-line treatment.[7] Outcome was noted as complete improvement (at discharge or during follow-up, whenever available) and partial improvement (with any neurological deficit at discharge or in subsequent follow-up).

Statistical analysis

Age was described as median years with an IQR. The diagnostic method used for NMDAR-E, clinical symptoms, treatment, imaging, and outcome were described as frequency or percentage. The proportion of various clinical variables between the adult and the pediatric cases were compared using Chi-square with Fischer's exact wherever applicable and odd's ratio and 95% confidence intervals were calculated.


   Results Top


Sixteen case series and 35 case reports totaling 249 cases were reported from India till June 2021.[8],[9],[10],[11],[12],[13],[14],[15],[16],[17],[18],[19],[20],[21],[22],[23],[24],[25],[26],[27],[28],[29],[30],[31],[32],[33],[34],[35],[36],[37],[38],[39],[40],[41],[42],[43],[44],[45],[46],[47],[48],[49],[50],[51],[52],[53],[54],[55],[56],[57] The salient features of these studies are tabulated in [Table 1] and [Table 2].
Table 1: Clinical profile, treatment, and outcome details of Indian NMDAR-E patients as reported in the case series

Click here to view
Table 2: Clinical profile, treatment and outcome details of NMDAR-E patients in the case reports

Click here to view


Analysis of the literature review of NMDAR-E cases from India

Demographic, clinical, imaging, treatment, and outcome details of 249 cases are tabulated in [Table 3]. These are described as follows:
Table 3: Demographic, clinical, imaging, treatment, and outcome details of all cases

Click here to view


Demography: The median age of presentation was 12 years (mean 6, IQR 17.5). The female-to-male ratio was 2.8:1 (n = 183/66). One hundred and sixty-eight (81.55%) cases were from the pediatric age group and 38 (18.44%) were from the adult age group (the age details of 43 patients were not known).

Clinical profile: The reports mentioned a constellation of symptoms and signs at presentation and during illness. Overall, MD and psychiatric abnormalities (70%) were the most common manifestations. This was followed by seizures (62%), language abnormalities (55%), cognitive deficits (40%), sleep disturbances (34%), encephalopathy (27%), and autonomic dysfunction (16%).

Adult versus pediatric: When compared to adults, encephalopathy and autonomic dysfunction were reported more commonly in pediatric patients, that is, 13% versus 32% (P = 0.019) and 3% versus 23% (P = 0.003), respectively. Cognitive deficits were more common in adult patients as compared with pediatric patients [74% vs. 27% (P = 0.00001)]. MD and seizures were reported more in the pediatric population, whereas psychiatric abnormalities, language abnormalities, and sleep disturbances were marginally higher in the adult population although no statistical significance could be derived [Table 4].
Table 4: Comparison of clinical profile and outcome between adult and pediatric NMDAR-E patients

Click here to view


Diagnosis of NMDAR-E: Antibodies against NMDAR were tested in CSF, serum, and both CSF+ serum in the cases analyzed. Of the 160 cases whose data were available, 43% of cases were diagnosed by both CSF+ serum antibodies, while 31% of the cases were diagnosed by antibodies in serum and 26% of cases by antibodies in CSF.

Triggers: Triggers of NMDAR-E were reported in 27 cases (11%). Out of these, 18 were due to various infectious agents (HSV 9, Japanese encephalitis virus [JEV] 4, dengue virus 1, Salmonella 1, Mycobacterium tuberculosis 1, Treponema pallidum 1, Leptospira 1). Of these Leptospira, Mycobacterium tuberculosis, Salmonella, and dengue as triggers of NMDAR-E were reported for the first time from India.[9],[15],[25],[33] Nine cases had ovarian tumors.

Other investigations: Of the 232 patients whose imaging details were available, 108 (46%) patients had abnormal imaging. The abnormalities were described in 108 patients and temporal lobe of the brain (38%) was the most commonly affected area. It was found that the pediatric patients had a predilection toward having a normal MRI despite florid clinical symptoms when compared to adults, that is, 65% versus 38% (P = 0.005). Details of EEG were available for 183 patients. The number of patients with abnormal EEG records was 5.6 times more than those with normal records, that is, 85% of the patients had an abnormal record. Details were described in 146 patients where diffuse slowing was the most common abnormality (68%). Thirty-one percent patients showed epileptiform discharges and delta brush pattern was only reported in 11% of the patients. Delta brush was more likely to be found in adults than in pediatric patients (P = 0.00005).

Treatment and outcome: Of the 221 patients whose treatment detail was available, 139 (62%) received only first-line treatment, that is, MPS, and/or IVIG, and/or PLEX and 92 (32%) received second-line treatment. RTX, azathioprine, MMF, cyclophosphamide, and oophorectomy were the second-line treatment used. Details of outcome were available for 213 patients. The patients were followed up for the period of 4–24 months in different studies.[19],[20] Of these, 61% had improved completely, 35% had residual neurological deficits, while 4% of the patients died. Wherever details were available, the major cause of death was ICU-related complications, mainly VAP, tracheostomy related, and autonomic dysfunction.[18],[28],[35],[41] Similarly, relapses were seen in 24 patients.[16],[17],[39],[44] The main presenting symptoms in those patients were seizures and psychiatric abnormalities.


   Discussion Top


We conducted a thorough literature search and analyzed the NMDAR-E cases from India which provided an overview of the clinical spectrum, treatment, and outcome of this disease. Further, we found some important differences between the pediatric and adult cases of NMDAR-E.

Demography: We found a lower median age at presentation among the Indian patients, that is, 12 years. In a study of 577 patients, Titulaer et al.[7] mention the median age to be 21 years where only 36% of the patients in that series were below 18 years of age. Similarly in a review, Dalmau et al.[4] also report the median age at presentation to be 21 years. Therefore, the lower median age was probably due to a higher percentage of pediatric patients (82%) in our review. Higher proportion of pediatrics patients reported in India can be attributed to some key factors: (1) increased awareness, hence more frequent diagnosis—Dalmau et al.[2] in their review opine that as awareness and understanding of the disease has increased, NMDAR-E was found more frequently in younger individuals and in those without teratomas,[2] that is, men and children. This was further substantiated by Gable et al.[58] in their seminal paper where they mentioned that more than 65% of total NMDAR-E occurs in individuals aged less than 18 years of age. Further, NMDAR-E as a cause for encephalitis upstaged viral etiologies and became the second common cause of encephalitis in children after ADEM. From India too, Chandra et al.[14] in their series of 29 patients mention 80% of their patients to be below 18 years of age. (2) Florance et al.[59] opine that infections can cause an overdrive of the immune system leading to NMDAR-E as corroborated by post-HSV NMDAR-E; these infections are an important factor for NMDAR-E in children and adolescents. (3) Reporting bias—As NMDAR-E in young adults and women were being reported frequently in literature, it is a plausibility that further reporting was biased toward atypical or rare cases leading to more publications in the pediatric age group. Therefore, a prospective study with large number of patients can solve this conundrum of higher proportion of pediatric patients reported in the Indian population.

Females constituted 74% of the total cases as compared to 26% males (3:1) reported from India. In both the adult and pediatric patients, females were affected more than males (67% and 75%, respectively). Dalmau et al.[4] and other studies[5],[60],[61],[62] also mention this as an important demographic finding. However, few case series from China reported male predominance; for example, Liu et al.[63] reported a series of 11 patients in which adults made up 99% and males constituted 55% of the total cases and Zhang et al.[64] in a series of 53 cases reported males to constitute 47% of the total cases. The authors attribute it to sample size and racial differences between Chinese and western population. In this regard, it can be inferred that in the Indian population, the sex distribution of NMDAR-E is similar to that reported from the Western world.

Clinical spectrum: Overall, psychiatric abnormalities, MD, seizures, and language abnormalities were the most common clinical features in the Indian cases of NMDAR-E. These findings are consistent with previously published series.[1],[5],[60],[61],[62],[63],[64] It can be inferred that the clinical spectrum also does not vary across different geographical areas.

Adults versus pediatric: Majority (82%) of the patients were from the pediatric age group. MD, seizures, encephalopathy, and autonomic dysfunctions were seen in a higher percentage of pediatric patients than in adults. Ho et al.[65] in their series of NMDAR-E in children from Hong Kong also reported that seizures, MD, and psychiatric abnormalities were the common clinical features. Similarly, a case series if 111 pediatric patients from southern China and a series of 32 patients from the USA reported these symptoms to be the common.[59],[66] Contrarily in adults, cognitive deficits, psychiatric abnormalities, sleep disturbances, and language abnormalities were seen in a higher percentage of patients in our review. Titular et al.[7] had reported that in adults, psychiatric abnormalities are present more commonly than in pediatric patients. We also found that in Indian patients, autonomic dysfunctions were predominantly reported in pediatric patients as compared to adults (22% vs. 5%). Eighty percent of the children (median age 14) were reported to have autonomic dysfunctions in a study by Florance et al.,[59] whereas other studies report 69% of the patients (median age 23)[1] and 40% of the patients (median age 26)[64] having autonomic dysfunctions. As the median age of the studies increased, the percentage of autonomic dysfunctions reported in them also seems to decrease. Whether this can imply that pediatric patients suffer from more autonomic dysfunctions than adults as reflected by our analysis is a question of further evaluation as autonomic dysfunctions have received little attention in prior studies and are both elusive and difficult to assess. Hence, drawing a conclusion can be an over-reach and further large studies are needed.

Neuroimaging: Forty-five percent of NMDAR-E patients from India had abnormal imaging with temporal lobe being the most involved structure of the brain (40%). Previous studies from the world reported 33–55% patients with an abnormal MRI.[1],[5] Dalmau et al.[4] had also reported that the temporal lobe was the most implicated anatomical structure in NMDAR-E. They also reported that the cortex, cerebellum, brainstem, and BG may be afflicted in NMDAR-E patients. We also found these structures to be involved in the reported Indian cases.

Further, we found that pediatric patients had normal MR imaging more frequently when compared to adults (65% vs. 40%, P = 0.015). Bacchi et al.[67] in a systematic review reported similar findings, that is, 65% of the pediatric patients (158/242) and 53% of adults (106/198) had a normal MR imaging. Contrary to this, Zhang et al.[64] report pediatric and adult patients to have similar percentages of normal MRI scans (53%, P = 0.991). Bacchi et al.[67] acknowledge the importance of the stage of the disease at which the MRI is done, as the abnormalities tend to decrease as the disease progresses. Zhang et al.[64] mention that the mean time of acquiring MR images in their study was 36 ± 15 days. Hence, although our review indicates the pediatric population to have fewer abnormalities on MRI, detailed studies focusing on MR imaging should be done to corroborate these findings as most studies in our review mentioned MRI as part of their routine patient workup without mentioning the time of acquisition of these scans. These findings also suggest that despite the presence of various florid clinical symptoms in NMDAR-E, MRI may be normal often. In this scenario, functional imaging like FDG-PET showing metabolic changes in various parts of the brain may aid in explaining the clinical findings.[68],[69]

EEG: EEG abnormalities were seen in 85% of the patients with diffuse slowing being the most common abnormality (68%) followed by epileptiform discharges (31%) and delta brush pattern (12%). Indian studies report that 78–100% of the patients have abnormal EEG patterns.[7],[12],[20] This is in concordance with studies from other parts of the world where 90–100% of patients had abnormal EEG patterns.[70],[71],[72] It is worth noting that more patients of NMDAR-E have an abnormal EEG than an abnormal MRI. In primary psychiatric illnesses, screening EEG abnormalities are seen only in 17–19% patients.[73],[74] Thus, an EEG becomes important in cases where the first manifestations are psychiatric or behavioral abnormalities, aiding the differentiation between a psychiatric illness and NMDAR-E. A systematic review by Gillinder et al.[75] reports epileptiform discharges in 18% of the patients and delta brush in 8% of the patients. They mention timing of EEG (whether in acute stage), duration of recording (initially 30% of the patients have normal records), and deep or widespread foci/functional abnormalities as probable reasons for reporting lesser focal findings vis-à-vis diffuse slowing.[75] Usually, studies report 18–30% of patients with the delta brush pattern[70],[71] but Meyer et al.[72] reported delta brush pattern in 53% of their patients. They conducted a median of 8 h of monitoring per patient and all of them were put on continuous EEG monitoring.[72] Hence, the yield of delta brush pattern increased in patients who were on continuous EEG monitoring.[4],[72] We also report adults to have a significantly higher percentage of delta brush pattern as compared to pediatric patients but as age-wise details were not specifically reported in the Indian literature, further studies would be needed to substantiate this EEG finding.

Triggers: Overall, 11% of patients in the review had a trigger for NMDAR-E. Infective causes as triggers were seen in 66% (18/27) of the cases with HSV being the commonest cause (44%). The other infections reported in the Indian cases were JEV, dengue virus, T. pallidum (syphilis), Salmonella typhi, Leptospira, and MTB. HSV as an important preceding infection triggering NMDAR-E has been highlighted by many case reports/series and in a review by Nosadini et al.[5] JEV and MTB as possible triggers have been reported in a review on non-HSV NMDAR-E cases by Cavaliere et al.[6] Our review of Indian studies appends S. typhi, dengue virus, M. tuberculosis, and Leptospira as non-HSV infections which can trigger NMDAR-E. Also, ovarian teratoma and adenomas were responsible for triggering NMDAR-E in nine Indian cases (seven adults, two pediatrics) in our review. Ovarian teratomas are the most common tumors responsible for NMDAR-E, although other tumors are also implicated in triggering NMDAR-E.[1],[4] Ovarian teratomas are postulated to express neuronal tissues and antigens against which antibodies are produced causing NMDAR-E.[76] The majority of cases with infective triggers were from the pediatric age group (90%). Previously published case series also reported that 32–80% of pediatric cases had evidence of infections before or concurrent to NMDAR-E.[1],[77],[78],[79],[80]

Treatment: Although no consensus guidelines exist for NMDAR-E treatment, the treatment protocol reported in Indian studies reflects the preference of clinicians toward MPS, IVIG, and RTX as published earlier by Titulaer et al.[7] Treatment details were available for 221 patients. Sixty-two percent (137) of the patients received first-line treatment (MPS and/or IVIG) and the rest (84) received additional second-line treatment. MPS was administered to 201 patients (only first line—137, first + second line—64) while IVIG was given to 123 patients (only first line—63, first + second line—60). RTX (48/84) was the most preferred drug for second-line treatment. Of the nine cases with ovarian tumors, five underwent oophorectomy. Two improved completely, in-fact there was rapid improvement leading to weaning off from ventilators within a week.[48],[51] Two patients had partial deficits and one patient died due to ICU complications. All patients had received immunotherapy. Dalmau et al.[1] mention that patients with early surgery along with immunotherapy benefit more than those who are not operated or operated late. Hence, patients with ovarian tumors should be operated after immunotherapy despite improvement as those who were not operated or operated late had higher chances of relapse.

Outcome: Of the 213 patients whose outcome details were available for analysis, nearly two-thirds of the patients improved completely, whereas one-third of them had partial deficits despite treatment (61% vs. 35%). The previous reports of deficits after NMDAR-E ranged between 27% and 85% of the patients.[1],[3],[5] The predictors for a better outcome in NMDAR_E patients have been noted to be an early institution of therapy, younger age, and better GCS (Glasgow coma scale >8) at admission.[5],[81] We could not analyze predictors for all the cases reported from India as majority of the papers were lacking the requisite details.

Strengths and limitations

The review analyzes the available data of all cases on NMDAR-E published from India to characterize that it is the clinical spectrum, treatment, and outcome. The limitations include, publication bias which may have led to a higher number of pediatric cases and their atypical presentation. Further, there was significant heterogeneity among the studies including definition of symptoms, treatment/management protocol, and missing data which precluded analysis of many aspects such as clinical symptoms, triggers, and predictors of outcome or hampered a robust assessment of the burden of certain aspects like symptoms, EEG, MRI, and treatment protocols. Also, the details about treatment, follow-up care, and disability were not mentioned in many reports, making it difficult to infer the standard clinical practice in the country with respect to NMDAR-E. Despite these limitations, our review provides for the first time a consolidated overview of various aspects of NMDAR-E from India. This overview of all cases from the country brings forth the Indian scenario of NMDAR-E while highlighting unique infective triggers. It also highlights the importance of a large prospective study of patients with NMDAR-E with uniform clinical definitions, treatment/management protocols, and follow-up of discharged patients to elucidate the clinical spectrum of NMDAR-E from India.


   Conclusions Top


Based on our review of 249 previously published cases from India, we conclude that NMDAR-E is reported more commonly in the pediatric population (82%) and in females (74%). A large prospective study/registry is needed to resolve the demographic profile of NMDAR-E in India. In the pediatric age group, seizures, MD, encephalopathy, and autonomic dysfunctions were more common while in adults had more cognitive deficits, psychiatric abnormalities, sleep disturbances, and language abnormalities. MRI abnormalities were seen in 45% of the patients. Pediatric patients had lesser MRI abnormalities as compared to adults. EEG abnormalities were seen in 85% of the patients, diffuse slowing being the commonest abnormality (68%). Delta brush was seen in 11% of the patients and significantly more in adults. Infections were important trigger factors for NMDAR-E. Though HSV infections were the commonest triggers, non-HSV infections can also trigger NMDAR-E. Indian neurologists have used MP, IVIG, and RTX and reported complete recovery in two-thirds of the patients.

Acknowledgments

The authors acknowledge the family members of the patients for their involvement in providing the clinical history of the patients. They also acknowledge the role of neurology residents of the institute in the care of the NMDAR-E patients.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25-36.  Back to cited text no. 1
    
2.
Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. AntiNMDAreceptor encephalitis: Case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091-8.  Back to cited text no. 2
    
3.
Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10:63-74.  Back to cited text no. 3
    
4.
Dalmau J, Armangué T, Planagumà J, Radosevic M, Mannara F, Leypoldt F, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: Mechanisms and models. Lancet Neurol 2019;18:1045-57.  Back to cited text no. 4
    
5.
Nosadini M, Mohammad SS, Corazza F, Ruga EM, Kothur K, Perilongo G, et al. Herpes simplex virus-induced anti-N-methyl-d-aspartate receptor encephalitis: A systematic literature review with analysis of 43 cases. Dev Med Child Neurol 2017;59:796-805.  Back to cited text no. 5
    
6.
Cavaliere E, Nosadini M, Pelizza MF, Ventura G, Toldo I, Sartori S. Anti-NMDAR encephalitis preceded by non-herpetic central nervous system infection: Systematic literature review and first case of tick-borne encephalitis triggering anti-NMDAR encephalitis. J Neuroimmunol 2019;332:1-7.  Back to cited text no. 6
    
7.
Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: An observational cohort study. Lancet Neurol 2013;12:157-65.  Back to cited text no. 7
    
8.
Datta AK, Pandit A, Biswas S, Biswas A, Roy BK, Gangopaddhyay G. Spectrum of anti-NMDA receptor antibody encephalitis: Clinical profile, management and outcomes. Ann Indian Acad Neurol 2021;24:383-9.  Back to cited text no. 8
  [Full text]  
9.
Raja P, Shamick B, Nitish LK, Holla VV, Pal PK, Mahadevan A, et al. Clinical characteristics, treatment and long-term prognosis in patients with anti-NMDAR encephalitis. Neurol Sci 2021;42:4683-96.  Back to cited text no. 9
    
10.
Chouksey A, Pandey S. Autoimmune movement disorders: A video-based case series of 11 patients. Eur Neurol 2021;84:124-8.  Back to cited text no. 10
    
11.
Roy AG, Vinayan KP, Kannoth S. New onset focal seizure clusters in children: Expanding the spectrum of anti NMDAR encephalitis. Neurol India 2020;68:1374-7.  Back to cited text no. 11
[PUBMED]  [Full text]  
12.
Gowda VK, Nagarajan B, Shivappa SK, Benakappa N. Seropositive Anti-NMDAR mediated autoimmune encephalitis. Indian J Pediatr 2020;87:961.  Back to cited text no. 12
    
13.
Nair A V, Menon J, Kuzhikkathukandiyil P. Clinical profile and neuropsychiatric outcome in children with anti-NMDAR encephalitis. Indian Pediatr 2019;56:247-9.  Back to cited text no. 13
    
14.
Chandra SR, Padmanabha H, Koti N, KalyaVyasaraj K, Mailankody P, Pai AR. N-Methyl-D-Aspartate encephalitis our experience with diagnostic dilemmas, clinical features, and outcome. J Pediatr Neurosci 2018;13:423-8.  Back to cited text no. 14
[PUBMED]  [Full text]  
15.
Goenka A, Jain V, Nariai H, Spiro A, Steinschneider M. Extended clinical spectrum of Anti-N-Methyl-d-Aspartate receptor encephalitis in children: A case series. Pediatr Neurol 2017;72:51-5.  Back to cited text no. 15
    
16.
Basheer S, Nagappa M, Mahadevan A, Bindu PS, Taly AB, Girimaji SC. Neuropsychiatric manifestations of pediatric NMDA receptor autoimmune encephalitis: A case series from a tertiary care center in India. Prim Care Companion CNS Disord 2017;19:17m02110. doi: 10.4088/PCC.17m02110.  Back to cited text no. 16
    
17.
Sudan YS, Vinayan KP, Roy AG, Wagh A, Kannoth S, Patil S. Clinical characteristics and follow-up of south Indian children with autoimmune encephalopathy. Indian J Pediatr 2016;83:1367-73.  Back to cited text no. 17
    
18.
Goenka A, Jain V. Anti-NMDA receptor encephalitis. Indian J Pediatr 2016;83:1032.  Back to cited text no. 18
    
19.
Suthar R, Saini AG, Sankhyan N, Sahu JK, Singhi P. Childhood anti-NMDA receptor encephalitis. Indian J Pediatr 2016;83:628-33.  Back to cited text no. 19
    
20.
Nagappa M, Bindu PS, Mahadevan A, Sinha S, Mathuranath PS, Taly AB. Clinical features, therapeutic response, and follow-up in pediatric anti-N-methyl-D-aspartate receptor encephalitis: Experience from a Tertiary Care University Hospital in India. Neuropediatrics 2016;47:24-32.  Back to cited text no. 20
    
21.
Cyril AC, Nair SS, Mathai A, Kannoth S, Thomas SV. Autoimmune encephalitis: Clinical diagnosis versus antibody confirmation. Ann Indian Acad Neurol 2015;18:408-11.  Back to cited text no. 21
[PUBMED]  [Full text]  
22.
Chakrabarty B, Tripathi M, Gulati S, Yoganathan S, Pandit AK, Sinha A, et al. Pediatric anti-N-methyl-D-aspartate (NMDA) receptor encephalitis: Experience of a tertiary care teaching center from north India. J Child Neurol 2014;29:1453-9.  Back to cited text no. 22
    
23.
Raha S, Gadgil P, Sankhla C, Udani V. Nonparaneoplastic anti-N-methyl-D-aspartate receptor encephalitis: A case series of four children. Pediatr Neurol 2012;46:246-9.  Back to cited text no. 23
    
24.
Datta AK, Chakraborty U, Dutta A, Malakar S, Pandit A. Claustrum hyperintensity as a marker of anti-NMDAR encephalitis. Postgrad Med J 2021:postgradmedj-2021-140396. doi: 10.1136/postgradmedj-2021-140396.  Back to cited text no. 24
    
25.
Panda PK, Sharawat IK, Bolia R. Leptospira triggered Anti-N-Methyl-d-Aspartate receptor encephalitis. J Trop Pediatr 2021;67:fmaa067.  Back to cited text no. 25
    
26.
Dubey S, Ghosh R, Dubey MJ, Sengupta S, Benito-León J, Ray BK. Bilateral thalamic changes in anti-NMDAR encephalitis presenting with hemichorea and dystonia and acute transient psychotic disorder. J Neuroimmunol 2020;347:577329. doi: 10.1016/j.jneuroim. 2020.577329.  Back to cited text no. 26
    
27.
Datta AK, Mukherjee A, Pandit A, Biswas A, Ray BK. Rabbit syndrome in anti-NMDAR antibody encephalitis: A unique association. Acta Neurol Belg 2020;120:1495-6.  Back to cited text no. 27
    
28.
Chheda A, Desai KM, Joshi R, Thakkar M, Pillai R, Walzade P, et al. A case of anti-NMDAR encephalitis with peculiar gyratory events that reignites the epilepsy versus movement disorders debate. Seizure 2020;83:193-6.  Back to cited text no. 28
    
29.
Koolwal A, Agrawal S, Koolwal GD, Saxena K, Daral A. Anti-N-methyl-D-aspartate receptor encephalitis: Case series of psychiatric presentations. Ann Indian Acad Neurol 2020;23:225-7.  Back to cited text no. 29
  [Full text]  
30.
Rizvi I, Garg RK, Malhotra HS, Kumar N, Uniyal R. Severe lingual and orofacial dyskinesias in AntiNMDA receptor encephalitis: A case report and review of Indian literature. Neurol India 2020;68:225-9.  Back to cited text no. 30
[PUBMED]  [Full text]  
31.
Cherian A, Divya KP, Shetty SC, Kannoth S, Thomas B. Coexistent MOG, NMDAR., CASPR2 antibody positivity: Triumph over the triumvirate. Mult Scler Relat Disord 2020;46:102468. doi: 10.1016/j.msard. 2020.102468.  Back to cited text no. 31
    
32.
John CM, Mathew DE, Abdelaziz M, Mahmoud AAH, AlOtaibi AD, Sohal APS. Anti-N-methyl-d-aspartate receptor encephalitis: A case series and review of the literature. J Pediatr Neurosci 2019;14:180-5.  Back to cited text no. 32
[PUBMED]  [Full text]  
33.
Garg M, Mittal J, Gupta P. Association of typhoid fever with anti-NMDAR encephalitis in a young child. J Neuroimmunol 2019;328:76-7.  Back to cited text no. 33
    
34.
Soni V, Sharawat IK, Kasinathan A, Saini L, Suthar R. Kluver-Bucy syndrome in a girl with anti-NMDAR encephalitis. Neurol India 2019;67:887-9.  Back to cited text no. 34
[PUBMED]  [Full text]  
35.
Prithvi A, Kesavan S, Saini AG, Suthar R, Mahadevan A. Little children, bigger problems: Anti-N-Methyl D-Aspartate receptor encephalitis! Indian J Pediatr 2019;86:1048-50.  Back to cited text no. 35
    
36.
Reddy MSS, Thippeswamy H, Ganjekar S, Nagappa M, Mahadevan A, Arvinda HR, et al. Anti-NMDA receptor encephalitis presenting as postpartum psychosis-a clinical description and review. Arch WomensMent Health 2018;21:465-9.  Back to cited text no. 36
    
37.
Grewal KS, Bhatia R, Singh N, Singh R, Dash D, Tripathi M. Confusional state in a pregnant woman: A case of NMDA receptor encephalitis during pregnancy. J Neuroimmunol 2018;325:29-31.  Back to cited text no. 37
    
38.
Palakkuzhiyil N, Uvais NA, Moideen S, Shihabudheen P. Anti-NMDA-receptor encephalitis presenting with catatonia in a middle-aged male. Asian J Psychiatr 2018;35:26-7.  Back to cited text no. 38
    
39.
Menon D, Menon RN, Kesavadas C, Mahadevan A, Radhakrishnan A, Kannoth S, et al. Clinical-radiological-pathological correlation in an unusual case of refractory epilepsy: A two-year journey of whodunit! Epileptic Disord 2018;20:51-9.  Back to cited text no. 39
    
40.
Shaik RS, Netravathi M, Nitish LK, Mani RS, Shah P, Damodar T, et al. A rare case of Japanese encephalitis-induced anti-N-methyl-d-aspartate receptor encephalitis. Neurol India 2018;66:1495-6.  Back to cited text no. 40
[PUBMED]  [Full text]  
41.
Kumari K, Sahni N, Kumari V, Saini V. Anti-N-methyl-D-aspartate-receptor encephalitis in young females. Turk J Anaesthesiol Reanim 2017;45:377-9.  Back to cited text no. 41
    
42.
Pastel H, Chakrabarty B, Saini L, Kumar A, Gulati S. A case of anti-N-methyl-D-aspartate (NMDA) receptor encephalitis possibly triggered by an episode of Japanese B encephalitis. Neurol India 2017;65:895-7.  Back to cited text no. 42
[PUBMED]  [Full text]  
43.
Chatterjee SS, Ghosal MK, Mitra S. Psychosis and catatonia as presenting features of anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis. Asian J Psychiatr 2017;27:112.  Back to cited text no. 43
    
44.
Patil VA, Kulkarni SD, Udwadia-Hegde A, Sayed RJ, Garg M. Anti-N-methyl-D-aspartate receptor encephalitis during relapse of herpes simplex encephalitis in a young boy: A brief review of literature. Neurol India 2017;65:393-7.  Back to cited text no. 44
[PUBMED]  [Full text]  
45.
Sharma P, Sagar R, Patra B, Saini L, Gulati S, Chakrabarty B. Psychotic symptoms in anti-N-methyl-d-aspartate (NMDA) receptor encephalitis: A case report and challenges. Asian J Psychiatr 2016;22:135-7.  Back to cited text no. 45
    
46.
Mythri SV, Mathew V. Catatonic syndrome in anti-NMDA receptor encephalitis. Indian J Psychol Med 2016;38:152-4.  Back to cited text no. 46
  [Full text]  
47.
Udani V, Desai N, Botre A. Partial manifestation of anti-NMDA-R encephalitis with predominant movement disorder. Mov Disord Clin Pract 2015;3:80-2.  Back to cited text no. 47
    
48.
Shaikh MA, Dhansura T, Gandhi S, Shaikh T. Anaesthetic management of a patient with anti-NMDA receptor encephalitis. Indian J Anaesth 2015;59:248-50.  Back to cited text no. 48
[PUBMED]  [Full text]  
49.
Mangalwedhe SB, Pandurangi AA, Pandurangi AK, Dugani RI. Anti-N-methyl-D-aspartate receptor encephalitis presenting with psychiatric symptoms. J Neuropsychiatry Clin Neurosci 2015;27:e152-3.  Back to cited text no. 49
    
50.
Kaur S, Juneja M, Mishra D, Jain S. Anti-N-methyl-D-aspartate receptor encephalitis: A case report and review of the literature. J Pediatr Neurosci 2014;9:145-7.  Back to cited text no. 50
[PUBMED]  [Full text]  
51.
Kattepur AK, Patil D, Shankarappa A, Swamy S, Chandrashekar NS, Chandrashekar P, et al. Anti-NMDAR limbic encephalitis--a clinical curiosity. World J Surg Oncol 2014;12:256. doi: 10.1186/1477-7819-12-256.  Back to cited text no. 51
    
52.
Shruthi TK, Shuba S, Rajakumar PS, Chitrambalam S. Anti-NMDA receptor encephalitis in an adolescent. Indian Pediatr 2014;51:405-6.  Back to cited text no. 52
    
53.
Kayal AK, Das M, Bhowmick S, Synmon B. Relapsing Anti-NMDAR Encephalitis after a gap of eight years in a girl from North-East India. Ann Indian Acad Neurol 2014;17:349-51.  Back to cited text no. 53
[PUBMED]  [Full text]  
54.
Sharma B, Handa R, Prakash S, Nagpal K, Gupta P. Anti-NMDA receptor encephalitis: A neurological disease in psychiatric disguise. Asian J Psychiatr 2014;7:92-4.  Back to cited text no. 54
    
55.
Suri V, Sharma S, Gupta R, Sogani SK, Mediratta S, Jadhao N. Pediatric anti-N methyl D aspartate receptor encephalitis. J Pediatr Neurosci 2013;8:120-2.  Back to cited text no. 55
[PUBMED]  [Full text]  
56.
Suri V, Sharma S, Gupta R, Jadhao N, Suri K. Young girl with abnormal behavior: Anti-N-Methyl-D-Aspartate receptor immune encephalitis. Ann Indian Acad Neurol 2013;16:169-71.  Back to cited text no. 56
[PUBMED]  [Full text]  
57.
Maramattom BV, Philip C, Sundaram PS. Idiopathic anti-NMDA-receptor encephalitis in a young Indian girl. Neurol India 2010;58:671-2.  Back to cited text no. 57
[PUBMED]  [Full text]  
58.
Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis 2012;54:899-904.  Back to cited text no. 58
    
59.
Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009;66:11-8.  Back to cited text no. 59
    
60.
Armangue T, Leypoldt F, Málaga I, Raspall-Chaure M, Marti I, Nichter C, et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol 2014;75:317-23.  Back to cited text no. 60
    
61.
Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, et al. N-methyl-D-aspartate antibody encephalitis: Temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010;133:1655-67.  Back to cited text no. 61
    
62.
Viaccoz A, Desestret V, Ducray F, Picard G, Cavillon G, Rogemond V, et al. Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. Neurology 2014;82:556-63.  Back to cited text no. 62
    
63.
Liu J, Wang D, Xiong Y, Liu B, Liu M. Anti-NMDAR encephalitis of 11 cases in China-detailed clinical, laboratory and imagiological description. Eur Neurol 2015;74:73-8.  Back to cited text no. 63
    
64.
Zhang T, Duan Y, Ye J, Xu W, Shu N, Wang C, et al. Brain MRI characteristics of patients with Anti-N-Methyl-D-Aspartate receptor encephalitis and their associations with 2-year clinical outcome. AJNR Am J Neuroradiol 2018;39:824-9.  Back to cited text no. 64
    
65.
Ho AC, Chan SH, Chan E, Wong SS, Fung ST, Cherk SW, et al. Anti-N-methyl-d-aspartate receptor encephalitis in children: Incidence and experience in Hong Kong. Brain Dev 2018;40:473-9.  Back to cited text no. 65
    
66.
Li X, Hou C, Wu WL, Liang H, Zheng K, Zhang Y, et al. Pediatric anti-N-methyl-d-aspartate receptor encephalitis in southern China: Analysis of 111 cases. J Neuroimmunol 2021;352:577479. doi: 10.1016/j.jneuroim. 2021.577479.  Back to cited text no. 66
    
67.
Bacchi S, Franke K, Wewegama D, Needham E, Patel S, Menon D. Magnetic resonance imaging and positron emission tomography in anti-NMDA receptor encephalitis: A systematic review. J Clin Neurosci 2018;52:54-9.  Back to cited text no. 67
    
68.
Yuan J, Guan H, Zhou X, Niu N, Li F, Cui L, et al. Changing brain metabolism patterns in patients with ANMDARE: Serial 18F-FDG PET/CT findings. Clin Nucl Med 2016;41:366-70.  Back to cited text no. 68
    
69.
Lagarde S, Lepine A, Caietta E, Pelletier F, Boucraut J, Chabrol B, et al. Cerebral (18) FluoroDeoxy-Glucose Positron Emission Tomography in paediatric anti N-methyl-D-aspartate receptor encephalitis: A case series. Brain Dev 2016;38:461-70.  Back to cited text no. 69
    
70.
Sonderen AV, Arends S, Tavy DLJ, Bastiaansen AEM, Bruijn MAAM, Schreurs MWJ, et al. Predictive value of electroencephalography in anti-NMDA receptor encephalitis. J Neurol Neurosurg Psychiatry 2018;89:1101-6.  Back to cited text no. 70
    
71.
Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D. Extreme delta brush: A unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 2012;79:1094-100.  Back to cited text no. 71
    
72.
Jeannin-Mayer S, André-Obadia N, Rosenberg S, Boutet C, Honnorat J, Antoine JC, et al. EEG analysis in anti-NMDA receptor encephalitis: Description of typical patterns. Clin Neurophysiol 2019;130:289-96.  Back to cited text no. 72
    
73.
Manchanda R, Malla A, Harricharan R, Cortese L, Takhar J. EEG abnormalities and outcome in first-episode psychosis. Can J Psychiatry 2003;48:722-6.  Back to cited text no. 73
    
74.
O'Sullivan SS, Mullins GM, Cassidy EM, McNamara B. The role of the standard EEG in clinical psychiatry. Hum Psychopharmacol 2006;21:265-71.  Back to cited text no. 74
    
75.
Gillinder L, Warren N, Hartel G, Dionisio S, O'Gorman C. EEG findings in NMDA encephalitis-A systematic review. Seizure 2019;65:20-4.  Back to cited text no. 75
    
76.
Dabner M, McCluggage WG, Bundell C, Carr A, Leung Y, Sharma R, et al. Ovarian teratoma associated with anti-N-methyl D-aspartate receptor encephalitis: A report of 5 cases documenting prominent intratumoral lymphoid infiltrates. Int J Gynecol Pathol 2012;31:429-37.  Back to cited text no. 76
    
77.
Armangue T, Titulaer MJ, Malaga I, Bataller L, Gabilondo I, Graus F, et al. Pediatric anti-N-methyl-D receptor encephalitis- clinical analysis and novel findings in a series of 20 patients. J Pediatr 2013;162 850-6.e2.  Back to cited text no. 77
    
78.
Sartori S, Nosadini M, Cesaroni E, Falsaperla R, Capovilla G, Beccaria F, et al. Paediatric anti-N-methyl-D receptor encephalitis: The first Italian multicenter case series. Eur J Paediatr Neurol 2015;19:453-63.  Back to cited text no. 78
    
79.
Zekeridou A, Karantoni E, Viaccoz A, Ducray F, Gitiaux C, Villega F, et al. Treatment and outcome of children and adolescents with N-methyl-D receptor encephalitis. J Neurol 2015;262:1859-66.  Back to cited text no. 79
    
80.
Brenton JN, Kim J, Schwartz RH. Approach to the management of pediatric-onset anti-N-methyl-D (Anti-NMDA) receptor encephalitis: A case series. J Child Neurol 2016;31:1150-5.  Back to cited text no. 80
    
81.
Chi X, Wang W, Huang C, Wu M, Zhang L, Li J, Zhou D. Risk factors for mortality in patients with anti-NMDA receptor encephalitis. Acta Neurol Scand 2017;136:298-304.  Back to cited text no. 81
    


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4]



 

Top
Print this article  Email this article

    

 
   Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Article in PDF (459 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
     Introduction
     Methods
     Results
     Discussion
     Conclusions
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed365    
    Printed13    
    Emailed0    
    PDF Downloaded41    
    Comments [Add]    

Recommend this journal